LONGITUDINAL CAPACITY REPORT
E. NAKAMURA · MRN 40128-CGenerated Jul 16, 2026 · UnDun Health
PATIENT CAPACITY REVIEW
Ellis Nakamura
67 yrs · Female · GLP-1 agonist · Reporting period Apr–Jul 2026 (12 weeks)
Patient view ↗
COMPOSITE · vs BASELINE
−0.8%
▼ Vitality declining · review advised
UNDUN INTELLIGENCE · SUMMARY
Composite sits at −0.8%, held up by stable cognitive and psychological domains, but vitality has fallen −4.8% and crossed the meaningful-change threshold four weeks ago. Resting heart rate is up 6 bpm and sleep has shortened. Consistent with under-recovery; onset aligns with the GLP-1 dose escalation on May 30.
FLAGGED THIS CYCLE
VITALITY −4.8%
RECOMMENDED ACTION
Message the patient; review recovery and sleep and rule out under-recovery before the next visit. Reassess the GLP-1 dose.
Concise view. Switch to Standard for domains and trajectory, or Comprehensive for the full workup: heat map, aging projection, intervention impact and labs.
Capacity by domain
| DOMAIN | vs BASELINE | 12-WK TREND | STATUS |
|---|---|---|---|
| Vitality | −4.8% | declining | MEANINGFUL |
| Locomotion | −0.6% | stable | STABLE |
| Cognitive | +1.2% | holding | STABLE |
| Psychological | +0.4% | holding | STABLE |
| Sensory | −0.2% | stable | STABLE |
Composite is the mean of the five domain scores, each expressed as percent from personal baseline.
Composite trajectory
Composite capacity, percent from personal baseline. Peak on May 12; sustained decline follows the May 30 dose escalation.
INTERVENTION TIMELINE
GLP-1 dose ↑
Sleep anchor
Suggested care plan
PRIORITY · REVIEW
UNDUN INTELLIGENCE · DECISION SUPPORT
Objective: Protect vitality and rule out under-recovery before the decline compounds.
FOLLOW-UP
Review recovery and sleep at next visit; rule out under-recovery or illness before attributing decline to disease.
MEDICATION
Reassess GLP-1 dose given alignment with the vitality decline and rising resting heart rate.
ADHERENCE
Reinforce circadian sleep-anchor adherence (currently 61%).
MONITORING
Re-evaluate composite in 4 weeks; escalate if vitality has not recovered above −3%.
Draft plan generated by UnDun Intelligence. Requires clinician review and sign-off before it takes effect.
Signed Date
Wearable vitals
Resting heart rate+6 bpm
HRV (rMSSD)−9%
Sleep duration6.2 h
Daily steps5,240
Data coverage92%
Active interventions
GLP-1 agonistDOSE ↑ MAY 30
Adherence 96%. Onset of vitality decline aligns with escalation.
Circadian sleep anchorACTIVE
Adherence 61%. Anchor times slipping later over last 3 weeks.
Week-by-week detail
W1
W2
W3
W4
Composite
−0.4
−0.6
−0.7
−0.8
Vitality
−2.2
−3.5
−4.1
−4.8
Locomotion
−0.3
−0.4
−0.5
−0.6
Cognitive
+0.5
+0.9
+1.0
+1.2
Psychological
+0.2
+0.3
+0.3
+0.4
Sensory
−0.1
−0.1
−0.2
−0.2
Each domain by week, percent from baseline. Composite is the row mean.
Sleep & recovery
Avg sleep duration6.2 h
Below 7–9 h target
Sleep consistency64%
Anchor times slipping
Deep sleep0.9 h
13% of night · low
REM sleep1.2 h
17% of night
Resting HR+6 bpm
Up vs last month
HRV (rMSSD)−9%
Declining
Body composition & activity
Weight−7.8%
On GLP-1
Lean mass−1.9%
Watch — mild loss
Body fat−3.1%
Down
Avg daily steps5,240
Below target
Zone 2 minutes70 / wk
Low
Active days16 / 30
Moderate
Measured intervention effect
Composite capacity in the four weeks before versus after each intervention started, isolating its measured effect.
| INTERVENTION | 4-WK PRE | 4-WK POST | Δ |
|---|---|---|---|
| GLP-1 dose escalation | +2.0% | −0.8% | −2.8% |
| Circadian sleep anchor | −0.6% | +0.1% | +0.7% |
Projected intervention impact
Estimated effect of each lever at target adherence, with the projected years of function preserved. Illustrative, model-based projections.
VITALITY · SLEEP
+6%
above baseline
3 yrs
delayed symptoms
Circadian sleep anchor
Fixed sleep / wake window+3%
Morning light exposure+2%
At-target adherence+1%
VITALITY · RECOVERY
+5%
above baseline
2 yrs
delayed symptoms
Recovery & light activity
Two light-activity days / wk+3%
Protected recovery window+2%
Domain heat map
On track
Watch
Concerning
Vitality
Locomotion
Cognitive
Psychological
Sensory
12 wk agonow
Weekly capacity status by domain, relative to personal baseline. Amber marks drift; red marks a crossed threshold.
Aging trajectory projection
YOUR TRAJECTORY
REFERENCE AGING
SYMPTOM THRESHOLD
At the current trajectory, projected to reach the symptom threshold near age 79. Recoverable if vitality rebounds.
Recent labs & biomarkers
| MARKER | VALUE | REF RANGE | FLAG |
|---|---|---|---|
| hs-CRP | 3.1 mg/L | <1.0 | HIGH |
| HbA1c | 5.8% | 4.8–5.6 | HIGH |
| Fasting insulin | 9 µIU/mL | 2–8 | HIGH |
| ApoB | 88 mg/dL | <90 | — |
| Vitamin D | 34 ng/mL | 30–50 | — |
| eGFR | 82 | >60 | — |
Most recent panel on file. Flags are relative to standard reference ranges, not personalized targets.
Reviewing clinician: Dr. A. Okafor · UnDun Health. This report summarizes passively collected wearable and body-composition data interpreted against the patient's own baseline. UnDun Intelligence findings are decision-support hypotheses, not diagnoses, and do not replace clinical judgment.